“…Numerous studies have been conducted to unveil the significant outcomes of isoprenoid-based manipulations of the mevalonate pathway and HMGCR in cancer cells. γ-Tocotrienol at 0–30 μM downregulated HMGCR, membrane H-, K-, and N-Ras, and Raf-1, p-AKT, and p-ERK in HL-60 cells (Chen et al, 2015), adding to a long list of in vitro and in vivo studies showing isoprenoid-mediated suppression of the growth of cancer cells including those of blood (Shoff et al, 1991; Melnykovych et al, 1992; Mo and Elson, 1999; Lee et al, 2015), breast (Iqbal et al, 2004; Pierpaoli et al, 2010, 2013; Gomide et al, 2013; Ding et al, 2017), cervix (Yazlovitskaya and Melnykovych, 1995; Xu et al, 2017; Potocnjak et al, 2018), colon (Mo and Elson, 1999; Gomide et al, 2013, 2016), liver (Wada et al, 2005; Crespo et al, 2013; Scolastici et al, 2014; Rodenak-Kladniew et al, 2018), lung (Mo and Elson, 1999; Wada et al, 2005; Gomide et al, 2013; Galle et al, 2014), mouth (Liang et al, 2013; Madankumar et al, 2013), pancreas (Hussein and Mo, 2009; Fernandes et al, 2013), prostate (Mo and Elson, 2004; Sundin et al, 2012; Fernandes et al, 2013; Jones et al, 2013; Yeganehjoo et al, 2017), skin (Mo et al, 2000; McAnally et al, 2007; Chang et al, 2009; Chaudhary et al, 2013), and stomach (Dong et al, 2013; Liu et al, 2013). Concomitantly, isoprenoids induce cell cycle arrest and apoptosis in the tumor cells (Mo and Elson, 1999, 2004; Dong et al, 2013; Jones et al, 2013; Yeganehjoo et al, 2017; Rodenak-Kladniew et al, 2018; Sailo et al, 2018).…”